Promising therapeutics with natural bioactive compounds for improving learning and memory - A review of randomized trials

Molecules

Volumn 17, Issue 9, 2012, Pages 10503-10539

  Kumar, Hemant ^a   More, Sandeep Vasant ^a   Han, Sang Don ^b   Choi, Jin Yong ^b   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Asarone; BT 11; Clinical trials; Cognition; EGb 761; GK501; Herbal medicines; Learning and memory; Panax gingseng; Tofu

Indexed keywords

NOOTROPIC AGENT; PLANT EXTRACT;

CHEMISTRY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; LEARNING; MEDICINAL PLANT; MEMORY; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

COGNITION DISORDERS; HUMANS; LEARNING; MEMORY; NEURODEGENERATIVE DISEASES; NOOTROPIC AGENTS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866927567     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules170910503     Document Type: Review

References (184)

1. Lye, T.C.; Piguet, O.; Grayson, D.A.; Creasey, H.; Ridley, L.J.; Bennett, H.P.; Broe, G.A. Hippocampal size and memory function in the ninth and tenth decades of life: The Sydney Older Persons Study. J. Neurol. Neurosurg. Psychiat. 2004, 75, 548-554.
2. Rusinek, H.; De Santi, S.; Frid, D.; Tsui, W.H.; Tarshish, C.Y.; Convit, A.; de Leon, M.J. Regional brain atrophy rate predicts future cognitive decline: 6-Year longitudinal MR imaging study of normal aging. Radiology 2003, 229, 691-696.
3. Ikarashi, Y.; Harigaya, Y.; Tomidokoro, Y.; Kanai, M.; Ikeda, M.; Matsubara, E.; Kawarabayashi, T.; Kuribara, H.; Younkin, S.G.; Maruyama, Y.; et al. Decreased level of brain acetylcholine and memory disturbance in APPsw mice. Neurobiol. Aging 2004, 25, 483-490.
4. Schliebs, R.; Arendt, T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural. Transm. 2006, 113, 1625-1644.
5. Bergmann, I.; Priestley, J.V.; McMahon, S.B.; Brocker, E.B.; Toyka, K.V.; Koltzenburg, M. Analysis of cutaneous sensory neurons in transgenic mice lacking the low affinity neurotrophin receptor p75. Eur. J. Neurosci. 1997, 9, 18-28.
6. Adams, M.; Gmunder, F.; Hamburger, M. Plants traditionally used in age related brain disorders - A survey of ethnobotanical literature. J. Ethnopharmacol. 2007, 113, 363-381.
7. Gijtenbeek, J.M.; van den Bent, M.J.; Vecht, C.J. Cyclosporine neurotoxicity: A review. J. Neurol. 1999, 246, 339-346.
8. Johnson, W.C.; Williford, W.O. Benefits, Morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study. J. Vasc. Surg. 2002, 35, 413-421.
9. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
10. Albuquerque, E.X.; Alkondon, M.; Pereira, E.F.; Castro, N.G.; Schrattenholz, A.; Barbosa, C.T.; Bonfante-Cabarcas, R.; Aracava, Y.; Eisenberg, H.M.; Maelicke, A. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 1997, 280, 1117-1136.
11. Schrattenholz, A.; Pereira, E.F.; Roth, U.; Weber, K.H.; Albuquerque, E.X.; Maelicke, A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 1996, 49, 1-6.
12. Bores, G.M.; Huger, F.P.; Petko, W.; Mutlib, A.E.; Camacho, F.; Rush, D.K.; Selk, D.E.; Wolf, V.; Kosley, R.W. Jr.; Davis, L.; et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther. 1996, 277, 728-738.
13. Rockwood, K.; Mintzer, J.; Truyen, L.; Wessel, T.; Wilkinson, D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J. Neurol. Neurosurg. Psychiat. 2001, 71, 589-595.
14. Tariot, P.N.; Solomon, P.R.; Morris, J.C.; Kershaw, P.; Lilienfeld, S.; Ding, C. A 5-month, Randomized, Placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000, 54, 2269-2276.
15. Raskind, M.A.; Peskind, E.R.; Wessel, T.; Yuan, W. Galantamine in AD: A 6-month randomized, Placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54, 2261-228.
16. Wilcock, G.K.; Lilienfeld, S.; Gaens, E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000, 321, 1445-1449.
17. Erkinjuntti, T.; Kurz, A.; Gauthier, S.; Bullock, R.; Lilienfeld, S.; Damaraju, C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002, 359, 1283-1290.
18. Burns, A.; Bernabei, R.; Bullock, R.; Cruz Jentoft, A.J.; Frolich, L.; Hock, C.; Raivio, M.; Triau, E.; Vandewoude, M.; Wimo, A.; et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, Placebo-controlled, Double-blind trial. Lancet Neurol. 2009, 8, 39-47.
19. Rockwood, K.; Fay, S.; Gorman, M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Int. J. Geriatr. Psychiat. 2010, 25, 191-201.
20. Liu, F.G.; Fang, Y.S.; Gao, Z.X.; Zuo, J.D.; Sou, M.L. Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease. Chin. J. Pharmacoepidemiol. 1995, 4, 196-198.
21. Ma, Y.X.; Zhu, Y.; Gu, Y.D.; Yu, Z.Y.; Yu, S.M.; Ye, Y.Z. Double-blind trial of huperzine-A (HUP) on cognitive deterioration in 314 cases of benign senescent forgetfulness, vascular dementia, and Alzheimer's disease. Ann. NY Acad. Sci. 1998, 854, 506-507.
22. Zhang, Z.; Wang, X.; Chen, Q.; Shu, L.; Wang, J.; Shan, G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 2002, 82, 941-944.
23. Rafii, M.S.; Walsh, S.; Little, J.T.; Behan, K.; Reynolds, B.; Ward, C.; Jin, S.; Thomas, R.; Aisen, P.S. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011, 76, 1389-1394.
24. Xu, Z.Q.; Liang, X.M.; Juan, W.; Zhang, Y.F.; Zhu, C.X.; Jiang, X.J. Treatment with Huperzine A improves cognition in vascular dementia patients. Cell. Biochem. Biophys. 2012, 62, 55-58.
25. Shishir, G.; Anand, S.; Navneet, K.; Vijay, T.; Meenal, T.; Manasi, T. Effect of Bacopa monnieri on Cognitive functions in Alzheimer's disease patients. Int. J. Collab. Res. Intern. Med. Public Health 2011, 3, 285-293.
26. Stough, C.; Lloyd, J.; Clarke, J.; Downey, L.A.; Hutchison, C.W.; Rodgers, T.; Nathan, P.J. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) 2001, 156, 481-484.
27. Stough, C.; Downey, L.A.; Lloyd, J.; Silber, B.; Redman, S.; Hutchison, C.; Wesnes, K.; Nathan, P.J. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 Day double-blind placebo-controlled randomized trial. Phytother. Res. 2008, 22, 1629-1634.
28. Calabrese, C.; Gregory, W.L.; Leo, M.; Kraemer, D.; Bone, K.; Oken, B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, Double-blind, Placebo-controlled trial. J. Altern. Complement Med. 2008, 14, 707-713.
29. Shin, K.Y.; Lee, J.Y.; Won, B.Y.; Jung, H.Y.; Chang, K.A.; Koppula, S.; Suh, Y.H. BT-11 is effective for enhancing cognitive functions in the elderly humans. Neurosci. Lett. 2009, 465, 157-159.
30. Lee, J.Y.; Kim, K.Y.; Shin, K.Y.; Won, B.Y.; Jung, H.Y.; Suh, Y.H. Effects of BT-11 on memory in healthy humans. Neurosci. Lett. 2009, 454, 111-114.
31. Kanowski, S.; Herrmann, W.M.; Stephan, K.; Wierich, W.; Horr, R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996, 29, 47-56.
32. Dongen, M.V.; van Rossum, E.; Kessels, A.; Sielhorst, H.; Knipschild, P. Ginkgo for elderly people with dementia and age-associated memory impairment: A randomized clinical trial. J. Clin. Epidem. 2003, 56, 367-376.
33. Mix, J.A.; Crews, W.D., Jr. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J. Altern. Complement Med. 2000, 6, 219-229.
34. Wesnes, K.A.; Ward, T.; McGinty, A.; Petrini, O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 2000, 152, 353-361.
35. Wattanathorn, J.; Mator, L.; Muchimapura, S.; Tongun, T.; Pasuriwong, O.; Piyawatkul, N.; Yimtae, K.; Sripanidkulchai, B.; Singkhoraard, J. Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica. J. Ethnopharmacol. 2008, 116, 325-332.
36. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol. Behav. 2002, 75, 739-751.
37. Sünram-Lea, S.I.; Birchall, R.J.; Wesnes, K.A.; Petrini, O. The Effect Of Acute Administration of 400 mg of Panax gingseng on Cognitive Performance and mood in Healthy Young Volunteers. Curr. Top. Nutraceu. Res. 2005, 3, 65-74.
38. Scholey, A.; Ossoukhova, A.; Owen, L.; Ibarra, A.; Pipingas, A.; He, K.; Roller, M.; Stough, C. Effects of American ginseng (Panax quinquefolius) on neurocognitive function: An acute, Randomised, Double-blind, Placebo-controlled, Crossover study. Psychopharmcology (Berl) 2010, 212, 345-356.
39. Reay, J.L.; Scholey, A.B.; Kennedy, D.O. Panax ginseng (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults. Hum. Psychopharmacol. 2010, 25, 462-471.
40. Chen, E.Y.; Hui, C.L. HT1001, A Proprietary North American Ginseng Extract, Improves Working Memory in Schizophrenia: A Double-blind, Placebo-Controlled Study. Phytother. Res. 2012, 26, 1166-1172.
41. Park, S.K.; Jung, I.C.; Lee, W.K.; Lee, Y.S.; Park, H.K.; Go, H.J.; Kim, K.; Lim, N.K.; Hong, J.T.; Ly, S.Y.; et al. A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: A double-blind placebo-controlled study. J. Med. Food 2011, 14, 334-343.
42. Kuriyama, S.; Hozawa, A.; Ohmori, K.; Shimazu, T.; Matsui, T.; Ebihara, S.; Awata, S.; Nagatomi, R.; Arai, H.; Tsuji, I. Green tea consumption and cognitive function: A cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr. 2006, 83, 355-361.
43. Ng, T.P.; Feng, L.; Niti, M.; Kua, E.H.; Yap, K.B. Tea consumption and cognitive impairment and decline in older Chinese adults. Am. J. Clin. Nutr. 2008, 88, 224-231.
44. Feng, L.; Gwee, X.; Kua, E.H.; Ng, T.P. Cognitive function and tea consumption in community dwelling older Chinese in Singapore. J. Nutr. Health Aging 2010, 14, 433-438.
45. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 2003, 28, 53-59.
46. Scholey, A.B.; Tildesley, N.T.; Ballard, C.G.; Wesnes, K.A.; Tasker, A.; Perry, E.K.; Kennedy, D.O. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl) 2008, 198, 127-139.
47. Moss, L.; Rouse, M.; Wesnes, K.A.; Moss, M. Differential effects of the aromas of Salvia species on memory and mood. Hum. Psychopharmacol. 2010, 25, 388-396.
48. Tildesley, N.T.; Kennedy, D.O.; Perry, E.K.; Ballard, C.G.; Wesnes, K.A.; Scholey, A.B. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol. Behav. 2005, 83, 699-709.
49. White, L.R.; Petrovitch, H.; Ross, G.W.; Masaki, K.; Hardman, J.; Nelson, J.; Davis, D.; Markesbery, W. Brain aging and midlife tofu consumption. J. Am. Coll. Nutr. 2000, 19, 242-255.
50. Kreijkamp-Kaspers, S.; Kok, L.; Grobbee, D.E.; de Haan, E.H.; Aleman, A.; van der Schouw, Y.T. Dietary phytoestrogen intake and cognitive function in older women. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62, 556-562.
51. Gaudig, M.; Richarz, U.; Han, J.; Van Baelen, B.; Schauble, B. Effects of galantamine in Alzheimer's disease: Double-blind withdrawal studies evaluating sustained versus interrupted treatment. Curr. Alzheimer Res. 2011, 8, 771-780.
52. Kavanagh, S.; Van Baelen, B.; Schauble, B. Long-term effects of galantamine on cognitive function in Alzheimer's disease: A large-scale international retrospective study. J. Alzheimer Dis. 2011, 27, 521-530.
53. Loy, C.; Schneider, L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane. Database Syst. Rev. 2006, 25, CD001747.
54. Watkins, P.B.; Zimmerman, H.J.; Knapp, M.J.; Gracon, S.I.; Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271, 992-928.
55. Thal, L.J.; Schwartz, G.; Sano, M.; Weiner, M.; Knopman, D.; Harrell, L.; Bodenheimer, S.; Rossor, M.; Philpot, M.; Schor, J.; Goldberg, A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 1996, 47, 1389-1395.
56. Rogers, S.L.; Doody, R.S.; Mohs, R.C.; Friedhoff, L.T. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, Double-blind, Placebo-controlled study. Donepezil Study Group. Arch. Intern. Med. 1998, 158, 1021-1031.
57. Liu, J.S.; Zhu, Y.L.; Yu, C.M.; Zhou, Y.Z.; Han, Y.Y.; Wu, F.W.; Qi, B.F. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can. J. Chem. 1986, 64, 837-839.
58. Zhang, H.Y.; Tang, X.C. Neuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease. Trends. Pharmacol .Sci. 2006, 27, 619-625.
59. Tang, X.C. Huperzine A (shuangyiping): A promising drug for Alzheimer's disease. Zhongguo Yao Li Xue Bao 1996, 17, 481-484.
60. Wang, R.; Yan, H.; Tang, X.C. Progress in studies of huperzine A, A natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006, 27, 1-26.
61. Chiu, H.F.; Zhang, M. Dementia research in China. Int. J. Geriatr. Psychiat. 2000, 15, 947-953.
62. Xu, S.S.; Cai, Z.; Cai, Z.Y.; Qu, Z.W.; Yang, R.M.; Cai, Y.L.; Wang, G.Q.; Su, X.Q.; Zhong, X.S.; Cheng, R.Y.; et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol. Sin. 1999, 20, 486-490.
63. Singh, H.; Dhawan, B. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa Monniera Linn. (Brahmi) Indian J. Pharmacol. 1997, 29, 359-365.
64. Ganguly, D.K.; Malhtora, C.L. Some neuropharmacological and behavioural effects of an active fraction from Herpestis monniera, Linn (Brahmi). Indian J. Physiol. Pharmacol. 1967, 11, 33-43.
65. Chatterji, N.; Rastogi, R.P.; Dhar, M.L. Chemical examination of Bacopa monniera Wettst.: Part I - isolation of chemical constituents. Indian. J. Chem. 1965, 3, 24-29.
66. Singh, H.K.; Rastogi, R.P.; Sriman, R.C.; Dhawan, B.N. Effect of bacoside A and B on avoidance response in rats. Phytother. Res. 1988, 2, 70-75.
67. Prakash, J.C.; Sirsi, M. Comparative study of the effects of Brahmi and chlorpromazine on motor learning in rats. J. Sci. Ins. Res. 1962, 21, 93-96.
68. Saraf, M.K.; Prabhakar, S.; Khanduja, K.L.; Anand, A. Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice. Evid. Based Complement Alternat. Med. 2011, 2011, 236186.
69. Russo, A.; Borrelli, F. Bacopa monniera, a reputed nootropic plant: An overview. Phytomed 2005, 12, 305-317.
70. Vohora, D.; Pal, S.N.; Pillai, K.K. Protection from phenytoin-induced cognitive deficit by Bacopa monniera, a reputed Indian nootropic plant. J. Ethnopharmacol. 2000, 71, 383-390.
71. Uabundit, N.; Wattanathorn, J.; Mucimapura, S.; Ingkaninan, K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J. Ethnopharmacol. 2010, 127, 26-31.
72. Das, A.; Shanker, G.; Nath, C.; Pal, R.; Singh, S.; Singh, H. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: Anticholinesterase and cognitive enhancing activities. Pharmacol. Biochem. Behav. 2002, 73, 893-900.
73. Bhattacharya, S.; Kumar, A.; Ghosal, S. Effect of Bacopa Monniera on Animal Models of Alzheimer's Disease and Perturbed Central Cholinergic Markers of Cognition in Rats; PJD: New York, NY, USA, 2000; pp. 21-32.
74. Bhattacharya, S.K.; Bhattacharya, A.; Kumar, A.; Ghosal, S. Antioxidant activity of Bacopa monniera in rat frontal cortex, Striatum and hippocampus. Phytother. Res. 2000, 14, 174-179.
75. Tripathi, Y.B.; Chaurasia, S.; Tripathi, E.; Upadhyay, A.; Dubey, G.P. Bacopa monniera Linn. as an antioxidant: Mechanism of action. Indian J. Exp. Biol. 1996, 34, 523-526.
76. del Cerro, S.; Arai, A.; Lynch, G. Inhibition of long-term potentiation by an antagonist of platelet-activating factor receptors. Behav. Neural. Biol. 1990, 54, 213-217.
77. Pravina, K.; Ravindra, K.R.; Goudar, K.S.; Vinod, D.R.; Joshua, A.J.; Wasim, P.; Venkateshwarlu, K.; Saxena, V.S.; Amit, A. Safety evaluation of BacoMind in healthy volunteers: A phase I study. Phytomed 2007, 14, 301-308.
78. Sharma, R.; Chaturvedi, C.; Tewari, P.V. Efficacy of Bacopa in revitalizing intellectual functions in children. J. Res. Edu. Indian Med. 1987, 1, 12.
79. Singh, R.H.; Singh, L. Studies on the anti-anxiety effect of the medyha rasayana drug Brahmi (Bacopa monniera Wettst.). Res. Ayur. Siddha. 1980, 1, 133-148.
80. Nathan, P.J.; Clarke, J.; Lloyd, J.; Hutchison, C.W.; Downey, L.; Stough, C. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum. Psychopharmacol. 2001, 16, 345-351.
81. Roodenrys, S.; Booth, D.; Bulzomi, S.; Phipps, A.; Micallef, C.; Smoker, J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology 2002, 27, 279-281.
82. Morgan, A.; Stevens, J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, Placebo-controlled, Double-blind trial. J. Altern. Complement Med. 2010, 16, 753-759.
83. Stough, C.K.; Pase, M.P.; Cropley, V.; Myers, S.; Nolidin, K.; King, R.; Camfield, D.; Wesnes, K.; Pipingas, A.; Croft, K.; et al. A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: The Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910). Nutr. J. 2012, 11, 11.
84. Mahadevan, S.; Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, Efficacy, Safety, and Uses. J. Food Sci. 2008, 73, R14-R19.
85. Xie, J.; Ding, C.; Ge, Q.; Zhou, Z.; Zhi, X. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2008, 864, 87-94.
86. Kleijnen, J.; Knipschild, P. Ginkgo biloba. Lancet 1992, 340, 1136-1139.
87. Barnes, P.M.; Bloom, B.; Nahin, R.L. Complementary and Alternative Medicine Use Among Adults and Children: Unites States, 2007. Natl. Health Stat. Report 2008, 1-23.
88. Itil, T.; Martorano, D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol. Bull. 1995, 31, 147-158.
89. Hoyer, S.; Lannert, H.; Noldner, M.; Chatterjee, S.S. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J. Neural. Transm. 1999, 106, 1171-1188.
90. Guidetti, C.; Paracchini, S.; Lucchini, S.; Cambieri, M.; Marzatico, F. Prevention of neuronal cell damage induced by oxidative stress in vitro: Effect of different Ginkgo biloba extracts. J. Pharm. Pharmacol. 2001, 53, 387-392.
91. Oyama, Y.; Fuchs, P.A.; Katayama, N.; Noda, K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 1994, 635, 125-129.
92. Tendi, E.A.; Bosetti, F.; Dasgupta, S.F.; Stella, A.M.; Drieu, K.; Rapoport, S.I. Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem. Res. 2002, 27, 319-323.
93. van Dongen, M.; van Rossum, E.; Kessels, A.; Sielhorst, H.; Knipschild, P. Ginkgo for elderly people with dementia and age-associated memory impairment: A randomized clinical trial. J. Clin. Epidemiol. 2003, 56, 367-376.
94. DeKosky, S.T.; Williamson, J.D.; Fitzpatrick, A.L.; Kronmal, R.A.; Ives, D.G.; Saxton, J.A.; Lopez, O.L.; Burke, G.; Carlson, M.C.; Fried, L.P.; et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 2008, 300, 2253-2262.
95. Napryeyenko, O.; Sonnik, G.; Tartakovsky, I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: Analyses of a randomised controlled trial. J. Neurol. Sci. 2009, 283, 224-229.
96. Kaschel, R. Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. Phytomed 2011, 18, 1202-1207.
97. Herrschaft, H.; Nacu, A.; Likhachev, S.; Sholomov, I.; Hoerr, R.; Schlaefke, S. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: A randomised, Placebocontrolled trial to confirm the efficacy and safety of a daily dose of 240 mg. J. Psychiatr. Res. 2012, 46, 716-723.
98. Kapoor, L. Handbook of Ayurvedic Medicinal Plants; CRC Press: Boca Raton, FL, USA, 1990.
99. Newall, C.A.; Anderson, L.; Phillipson, J.D. Herbal Medicines: A Guide for Healthcare Professionals; In Pharmaceutical Press: London, UK, 1996.
100. Pan, J.; Kai, G.; Yuan, C.; Zhou, B.; Jin, R.; Yuan, Y. Separation and determination of madecassic acid in extracts of Centella asiatica using high performance liquid chromatography with β-cyclodextrin as mobile phase additive. Chi. J. Chromatogr. 2007, 25, 316-318.
101. Williamson, E. Major Herbs of Ayurveda; Elsevier Science: London, UK, 2002; pp. 102-110.
102. Sharma, P.V. Dravyaguna Vignana, 13th ed.; Chaukhamba Vishwa Bharati Academy: New Delhi, India, 1992; pp. 3-5.
103. Rao, S.B.; Chetana, M.; Uma Devi, P. Centella asiatica treatment during postnatal period enhances learning and memory in mice. Physiol. Behav. 2005, 86, 449-457.
104. Veerendra Kumar, M.H.; Gupta, Y.K. Effect of different extracts of Centella asiatica on cognition and markers of oxidative stress in rats. J. Ethnopharmacol. 2002, 79, 253-260.
105. Veerendra Kumar, M.H.; Gupta, Y.K. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Clin. Exp. Pharmacol. Physiol. 2003, 30, 336-342.
106. Mukherjee, P.K.; Kumar, V.; Houghton, P.J. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother. Res. 2007, 21, 1142-1145.
107. Gadahad, M.R.; Rao, M.; Rao, G. Enhancement of hippocampal CA3 neuronal dendritic arborization by Centella asiatica (Linn) fresh leaf extract treatment in adult rats. J. Chi. Med. Assoc. 2008, 71, 6-13.
108. Mohandas Rao, K.G.; Muddanna Rao, S.; Gurumadhva Rao, S. Enhancement of Amygdaloid Neuronal Dendritic Arborization by Fresh Leaf Juice of Centella asiatica (Linn) During Growth Spurt Period in Rats. Evid. Based Compl.Alternat. Med. 2009, 6, 203-210.
109. Dhanasekaran, M.; Holcomb, L.A.; Hitt, A.R.; Tharakan, B.; Porter, J.W.; Young, K.A.; Manyam, B.V. Centella asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. Phytother. Res. 2009, 23, 14-19.
110. Shobi, V.; Goel, H.C. Protection against radiation-induced conditioned taste aversion by Centella asiatica. Physiol.Behav. 2001, 73, 19-23.
111. Kumar, A.; Prakash, A.; Dogra, S. Centella asiatica Attenuates D-Galactose-Induced Cognitive Impairment, Oxidative and Mitochondrial Dysfunction in Mice. Int. J. Alzheimer. Dis. 2011, 2011, 347569.
112. De Souza, N.D.; Shah, V.; Desai, P.D.; Inamdar, P.K.; Sa, A.D.; Ammonamanchi, R. 2,3,23-trihydroxy-urs-12-ene and its derivatives, Processes for their preparation and their use. EP0383171, 22 August 1990.
113. Mook-Jung, I.; Shin, J.E.; Yun, S.H.; Huh, K.; Koh, J.Y.; Park, H.K.; Jew, S.S.; Jung, M.W. Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity. J. Neurosci. Res. 1999, 58, 417-425.
114. Dev, R.D.O.; Mohamed, S.; Hambali, Z.; Samah, B.A. Comparison on cognitive effects of Centella asiatica in healthy middle age female and male volunteers. Eur. J. Sci. Res. 2009, 31, 553-565.
115. Tiwari, S.; Singh, S.; Patwardhan, K.; Gehlot, S.; Gambhir, I.S. Effect of Centella asiatica on mild cognitive impairment (MCI) and other common age-related clinical problems. Dig. J. Nanomater. Bios.2008, 3, 215-220.
116. Zhao, H.; Li, Q.; Zhang, Z.; Pei, X.; Wang, J.; Li, Y. Long-term ginsenoside consumption prevents memory loss in aged SAMP8 mice by decreasing oxidative stress and up-regulating the plasticity-related proteins in hippocampus. Brain Res. 2009, 1256, 111-122.
117. Lee, J.H.; Kim, S.R.; Bae, C.S.; Kim, D.; Hong, H.; Nah, S. Protective effect of ginsenosides, Active ingredients of Panax ginseng, On kainic acid-induced neurotoxicity in rat hippocampus. Neurosci. Lett. 2002, 325, 129-133.
118. Chu, S.F.; Zhang, J.T. New achievements in ginseng research and its future prospects. Chin. J. Integr. Med. 2009, 15, 403-408.
119. Yang, J.H.; Han, S.J.; Ryu, J.H.; Jang, I.S.; Kim, D.H. Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice. Biol. Pharm. Bull. 2009, 32, 1710-1705.
120. Nishiyama, N.; Cho, S.I.; Kitagawa, I.; Saito, H. Malonylginsenoside Rb1 potentiates nerve growth factor (NGF)-induced neurite outgrowth of cultured chick embryonic dorsal root ganglia. Biol. Pharm. Bull. 1994, 17, 509-513.
121. Xue, J.F.; Liu, Z.J.; Hu, J.F.; Chen, H.; Zhang, J.T.; Chen, N.H. Ginsenoside Rb1 promotes neurotransmitter release by modulating phosphorylation of synapsins through a cAMP-dependent protein kinase pathway. Brain Res. 2006, 1106, 91-98.
122. Liu, L.; Hoang-Gia, T.; Wu, H.; Lee, M.R.; Gu, L.; Wang, C.; Yun, B.S.; Wang, Q.; Ye, S.; Sung, C.K. Ginsenoside Rb1 improves spatial learning and memory by regulation of cell genesis in the hippocampal subregions of rats. Brain Res. 2011, 1382, 147-154.
123. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr. Neurosci. 2001, 4, 295-310.
124. More, S.V.; Koppula, S.; Kim, I.S.; Kumar, H.; Kim, B.W.; Choi, D.K. The role of bioactive compounds on the promotion of neurite outgrowth. Molecules 2012, 17, 6728-5753.
125. Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M.B. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin- 3-gallate: Implications for neurodegenerative diseases. J. Neurochem. 2004, 88, 1555-1569.
126. Hong, J.T.; Ryu, S.R.; Kim, H.J.; Lee, J.K.; Lee, S.H.; Kim, D.B.; Yun, Y.P.; Ryu, J.H.; Lee, B.M.; Kim, P.Y. Neuroprotective effect of green tea extract in experimental ischemiareperfusion brain injury. Brain Res. Bull. 2000, 53, 743-749.
127. Hong, J.T.; Ryu, S.R.; Kim, H.J.; Lee, J.K.; Lee, S.H.; Yun, Y.P.; Lee, B.M.; Kim, P.Y. Protective effect of green tea extract on ischemia/reperfusion- induced brain injury in Mongolian gerbils. Brain Res. 2001, 888, 11-18.
128. Nanjo, F.; Goto, K.; Seto, R.; Suzuki, M.; Sakai, M.; Hara, Y. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic. Biol. Med. 1996, 21, 895-902.
129. Nanjo, F.; Mori, M.; Goto, K.; Hara, Y. Radical scavenging activity of tea catechins and their related compounds. Biosci. Biotechnol. Biochem. 1999, 63, 1621-1623.
130. Choi, Y.T.; Jung, C.H.; Lee, S.R.; Bae, J.H.; Baek, W.K.; Suh, M.H.; Park, J.; Park, C.W.; Suh, S.I. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci. 2001, 70, 603-614.
131. Guo, Q.; Zhao, B.; Li, M.; Shen, S.; Xin, W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta 1996, 1304, 210-222.
132. Takeda, A.; Sakamoto, K.; Tamano, H.; Fukura, K.; Inui, N.; Suh, S.W.; Won, S.J.; Yokogoshi, H. Facilitated neurogenesis in the developing hippocampus after intake of theanine, an amino acid in tea leaves, and object recognition memory. Cell. Mol. Neurobiol. 2011, 31, 1079-1088.
133. Assuncao, M.; Santos-Marques, M.J.; Carvalho, F.; Lukoyanov, N.V.; Andrade, J.P. Chronic green tea consumption prevents age-related changes in rat hippocampal formation. Neurobiol. Aging 2011, 32, 707-717.
134. Mandel, S.A.; Amit, T.; Weinreb, O.; Youdim, M.B. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 2011, 25, 187-208.
135. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci. 2011, 12, 5592-5603.
136. Nurk, E.; Refsum, H.; Drevon, C.A.; Tell, G.S.; Nygaard, H.A.; Engedal, K.; Smith, A.D. Intake of flavonoid-rich wine, Tea, and Chocolate by elderly men and women is associated with better cognitive test performance. J. Nutr. 2009, 139, 120-127.
137. Huang, C.Q.; Dong, B.R.; Zhang, Y.L.; Wu, H.M.; Liu, Q.X. Association of cognitive impairment with smoking, Alcohol consumption, Tea consumption, and Exercise among Chinese nonagenarians/centenarians. Cogn. Behav. Neurol. 2009, 22, 190-196.
138. Tabernaemontanus, D.I.T. Kräuterbuch; Johann Ludwig König/Johann Brandmüller: Basel, Switzerland, 1987.
139. Savelev, S.U.; Okello, E.J.; Perry, E.K. Butyryl- and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother. Res. 2004, 18, 315-324.
140. Sfikas, G. Heilpflanzen Griechenlands; Efstathiadis Group: Athen, Greece, 1980.
141. Imanshahidi, M.; Hosseinzadeh, H. The pharmacological effects of Salvia species on the central nervous system. Phytother. Res. 2006, 20, 427-437.
142. Kurzer, M.S.; Xu, X. Dietary phytoestrogens. Annu. Rev. Nutr. 1997, 17, 353-381.
143. COT report. Phytoestrogens and Health, Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Food Standard Agency: London, UK, 2003; pp. 1-444.
144. United Soybean Board. 16th Annual Survey: Consumer Attitudes About Nutrition. Available online: http://www.soyconnection.com/health-nutrition/ consumer-attitudes.php (accessed on 1 July 2009).
145. Lund, T.D.; West, T.W.; Tian, L.Y.; Bu, L.H.; Simmons, D.L.; Setchell, K.D.; Adlercreutz, H.; Lephart, E.D. Visual spatial memory is enhanced in female rats (but inhibited in males) by dietary soy phytoestrogens. BMC Neurosci. 2001, 2, 20.
146. Chen, J.; Quan, M.H.; Cheng, Y.Q.; Sun, J.; Li, L.T. Acetylcholinesterase inhibitory activity of Chinese sufu (fermented tofu) ethanol-extract. Food Chem. 2012, 134, 1263-1266.
147. Hogervorst, E.; Sadjimim, T.; Yesufu, A.; Kreager, P.; Rahardjo, T.B. High tofu intake is associated with worse memory in elderly Indonesian men and women. Dement. Geriatr. Cogn. Disord. 2008, 26, 50-57.
148. Henderson, V.W.; St John, J.A.; Hodis, H.N.; Kono, N.; McCleary, C.A.; Franke, A.A.; Mack, W.J. Long-term soy isoflavone supplementation and cognition in women: A randomized, controlled trial. Neurology 2012, 78, 1841-1848.
149. Greendale, G.A.; Huang, M.H.; Leung, K.; Crawford, S.L.; Gold, E.B.; Wight, R.; Waetjen, E.; Karlamangla, A.S. Dietary phytoestrogen intakes and cognitive function during the menopausal transition: Results from the Study of Women's Health Across the Nation Phytoestrogen Study. Menopause 2012, 19, 894-903.
150. Liu, W.B.; Liu, W.Z. Disciplinarian investigation of Chinese complex prescription with promoting intelligence in past dynasties. Jiangxi. J. Trad. Chin. Med. 2005, 36, 62-63.
151. Ikeya, Y.; Takeda, S.; Tunakawa, M.; Karakida, H.; Toda, K.; Yamaguchi, T.; Aburada, M. Cognitive improving and cerebral protective effects of acylated oligosaccharides in Polygala tenuifolia. Biol. Pharm. Bull. 2004, 27, 1081-1085.
152. Sun, X.L.; Ito, H.; Masuoka, T.; Kamei, C.; Hatano, T. Effect of Polygala tenuifolia root extract on scopolamine-induced impairment of rat spatial cognition in an eight-arm radial maze task. Biol. Pharm. Bull. 2007, 30, 1727-1731.
153. Zhang, H.; Han, T.; Zhang, L.; Yu, C.H.; Wan, D.G.; Rahman, K.; Qin, L.P.; Peng, C. Effects of tenuifolin extracted from radix polygalae on learning and memory: A behavioral and biochemical study on aged and amnesic mice. Phytomedicine 2008, 15, 587-594.
154. Park, C.H.; Choi, S.H.; Koo, J.W.; Seo, J.H.; Kim, H.S.; Jeong, S.J.; Suh, Y.H. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11. J. Neurosci. Res. 2002, 70, 484-492.
155. Shin, K.Y.; Won, B.Y.; Heo, C.; Kim, H.J.; Jang, D.P.; Park, C.H.; Kim, S.; Kim, H.S.; Kim, Y.B.; Lee, H.G.; et al. BT-11 improves stress-induced memory impairments through increment of glucose utilization and total neural cell adhesion molecule levels in rat brains. J. Neurosci. Res. 2009, 87, 260-268.
156. Xu, S.P.; Yang, Y.Y.; Xue, D.; Liu, J.X.; Liu, X.M.; Fan, T.P.; le Pan, R.; Li, P. Cognitive-enhancing effects of polygalasaponin hydrolysate in abeta(25-35)-induced amnesic mice. Evid. Based Complement Alternat. Med. 2011, 2011, 839720.
157. Tohda, C.; Matsumoto, N.; Zou, K.; Meselhy, M.R.; Komatsu, K. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology 2004, 29, 860-868.
158. Jia, H.; Jiang, Y.; Ruan, Y.; Zhang, Y.; Ma, X.; Zhang, J.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci. Lett. 2004, 367, 123-128.
159. Park, H.J.; Lee, K.; Heo, H.; Lee, M.; Kim, J.W.; Whang, W.W.; Kwon, Y.K.; Kwon, H. Effects of Polygala tenuifolia root extract on proliferation of neural stem cells in the hippocampal CA1 region. Phytother. Res. 2008, 22, 1324-1329.
160. Xue, W.; Hu, J.F.; Yuan, Y.H.; Sun, J.D.; Li, B.Y.; Zhang, D.M.; Li, C.J.; Chen, N.H. Polygalasaponin XXXII from Polygala tenuifolia root improves hippocampal-dependent learning and memory. Acta Pharmacol. Sin. 2009, 30, 1211-1219.
161. Limon, I.D.; Mendieta, L.; Diaz, A.; Chamorro, G.; Espinosa, B.; Zenteno, E.; Guevara, J. Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-beta((25-35)). Neurosci. Lett. 2009, 453, 98-103.
162. Mukherjee, P.K.; Kumar, V.; Mal, M.; Houghton, P.J. In vitro acetylcholinesterase inhibitory activity of the essential oil from Acorus calamus and its main constituents. Planta Med. 2007, 73, 283-285.
163. Kumar, H.; Kim, B.W.; Song, S.Y.; Kim, J.S.; Kim, I.S.; Kwon, Y.S.; Koppula, S.; Choi, D.K. Cognitive Enhancing Effects of Alpha Asarone in Amnesic Mice by Influencing Cholinergic and Antioxidant Defense Mechanisms. Biosci. Biotechnol. Biochem. 2012, 76, 1518-1522.
164. Ammon, H.P.; Wahl, M.A. Pharmacology of Curcuma longa. Planta Med. 1991, 57, 1-7.
165. Reeta, K.H.; Mehla, J.; Gupta, Y.K. Curcumin is protective against phenytoin-induced cognitive impairment and oxidative stress in rats. Brain Res. 2009, 1301, 52-60.
166. Ali, E.H.; Arafa, N.M. Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction. Fitoterapia 2011, 82, 601-608.
167. Jaques, J.A.; Rezer, J.F.; Carvalho, F.B.; da Rosa, M.M.; Gutierres, J.M.; Goncalves, J.F.; Schmatz, R.; de Bairros, A.V.; Mazzanti, C.M.; Rubin, M.A.; et al. Curcumin protects against cigarette smoke-induced cognitive impairment and increased acetylcholinesterase activity in rats. Physiol. Behav. 2012, 106, 664-669.
168. Yadav, R.S.; Chandravanshi, L.P.; Shukla, R.K.; Sankhwar, M.L.; Ansari, R.W.; Shukla, P.K.; Pant, A.B.; Khanna, V.K. Neuroprotective efficacy of curcumin in arsenic induced cholinergic dysfunctions in rats. Neurotoxicology 2011, 32, 760-768.
169. Awasthi, H.; Tota, S.; Hanif, K.; Nath, C.; Shukla, R. Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sci. 2010, 86, 87-94.
170. Xu, Y.; Lin, D.; Li, S.; Li, G.; Shyamala, S.G.; Barish, P.A.; Vernon, M.M.; Pan, J.; Ogle, W.O. Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress. Neuropharmacology 2009, 57, 463-471.
171. Ng, T.P.; Chiam, P.C.; Lee, T.; Chua, H.C.; Lim, L.; Kua, E.H. Curry consumption and cognitive function in the elderly. Am. J. Epidemiol. 2006, 164, 898-906.
172. Tarantilis, P.A.; Tsoupras, G.; Polissiou, M. Determination of saffron (Crocus sativus L.) components in crude plant extract using high-performance liquid chromatography-UV-visible photodiode-array detection-mass spectrometry. J. Chromatogr. A 1995, 699, 107-118.
173. Pitsikas, N.; Sakellaridis, N. Crocus sativus L. extracts antagonize memory impairments in different behavioural tasks in the rat. Behav. Brain Res. 2006, 173, 112-115.
174. Akhondzadeh, S.; Sabet, M.S.; Harirchian, M.H.; Togha, M.; Cheraghmakani, H.; Razeghi, S.; Hejazi, S.; Yousefi, M.H.; Alimardani, R.; Jamshidi, A.; et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: A 16-week, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 2010, 35, 581-588.
175. Akhondzadeh, S.; Shafiee Sabet, M.; Harirchian, M.H.; Togha, M.; Cheraghmakani, H.; Razeghi, S.; Hejazi, S.S.; Yousefi, M.H.; Alimardani, R.; Jamshidi, A.; et al. A 22-week, Multicenter, Randomized, Double-blind controlled trial of Crocus sativus in the treatment of mild-tomoderate Alzheimer's disease. Psychopharmacology (Berl) 2010, 207, 637-643.
176. Wheatley, D. Medicinal plants for insomnia: A review of their pharmacology, efficacy and tolerability. J. Psychopharmacol. 2005, 19, 414-421.
177. Kennedy, D.O.; Scholey, A.B.; Tildesley, N.T.; Perry, E.K.; Wesnes, K.A. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol. Biochem. Behav. 2002, 72, 953-964.
178. Ballard, C.G.; O'Brien, J.T.; Reichelt, K.; Perry, E.K. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind, placebo-controlled trial with Melissa. J. Clin. Psychiat. 2002, 63, 553-558.
179. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. J. Neurol. Neurosurg. Psychiat. 2003, 74, 863-866.
180. Duarte, J.M.; Agostinho, P.M.; Carvalho, R.A.; Cunha, R.A. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 2012, 7, e21899.
181. Smith, A.P.; Clark, R.; Gallagher, J. Breakfast cereal and caffeinated coffee: Effects on working memory, attention, mood, and cardiovascular function. Physiol. Behav. 1999, 67, 9-17.
182. Hawkes, C.; Harris, J.L. An analysis of the content of food industry pledges on marketing to children. Public Health Nutr. 2011, 14, 1403-1414.
183. Kaur, T.; Pathak, C.M.; Pandhi, P.; Khanduja, K.L. Effects of green tea extract on learning, memory, behavior and acetylcholinesterase activity in young and old male rats. Brain Cogn. 2008, 67, 25-30.
184. Unno, K.; Takabayashi, F.; Yoshida, H.; Choba, D.; Fukutomi, R.; Kikunaga, N.; Kishido, T.; Oku, N.; Hoshino, M. Daily consumption of green tea catechin delays memory regression in aged mice. Biogerontology 2007, 8, 89-95.